Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iptacopan Roll-over Extension in PNH
NCT04747613Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Jul 2021
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 17
01
Overview
A Phase 3 trial of Iptacopan in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Novartis. Started Jul 2021; status: active, not recruiting.
02
Drugs
Iptacopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT04747613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04747613.